These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 29704897)

  • 21. Levonorgestrel concentrations during 7 years of continuous use of Jadelle contraceptive implants.
    Sivin I; Wan L; Ranta S; Alvarez F; Brache V; Mishell DR; Darney P; Biswas A; Diaz S; Kiriwat O; Anant MP; Klaisle C; Pavez M; Schechter J
    Contraception; 2001 Jul; 64(1):43-9. PubMed ID: 11535213
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contraceptive implants.
    McDonald-Mosley R; Burke AE
    Semin Reprod Med; 2010 Mar; 28(2):110-7. PubMed ID: 20352560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transition from Norplant to Jadelle in a clinic with extensive experience providing contraceptive implants.
    Brache V; Faundes A; Alvarez F; García AG
    Contraception; 2006 Apr; 73(4):364-7. PubMed ID: 16531168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sino-implant (II)--a levonorgestrel-releasing two-rod implant: systematic review of the randomized controlled trials.
    Steiner MJ; Lopez LM; Grimes DA; Cheng L; Shelton J; Trussell J; Farley TM; Dorflinger L
    Contraception; 2010 Mar; 81(3):197-201. PubMed ID: 20159174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous use of a levonorgestrel intrauterine system and an etonogestrel subdermal implant for debilitating adolescent endometriosis.
    Al-Jefout M; Palmer J; Fraser IS
    Aust N Z J Obstet Gynaecol; 2007 Jun; 47(3):247-9. PubMed ID: 17550495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II--clinical trial with biodegradable subdermal contraceptive implant Capronor (4.0-cm single implant). Indian Council of Medical Research Task Force on Hormonal Contraception.
    Contraception; 1991 Oct; 44(4):409-17. PubMed ID: 1756628
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Subdermal progestin implant contraception.
    Darney PD
    Curr Opin Obstet Gynecol; 1991 Aug; 3(4):470-6. PubMed ID: 1908716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multicenter randomized clinical trial of one-rod etonogestrel and two-rod levonorgestrel contraceptive implants with nonrandomized copper-IUD controls: methodology and insertion data.
    Meirik O; Brache V; Orawan K; Habib NA; Schmidt J; Ortayli N; Culwell K; Jackson E; Ali M;
    Contraception; 2013 Jan; 87(1):113-20. PubMed ID: 23063337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endometrial expression of glycodelin in women with levonorgestrel-releasing subdermal implants.
    Mandelin E; Koistinen H; Koistinen R; Arola J; Affandi B; Seppälä M
    Fertil Steril; 2001 Sep; 76(3):474-8. PubMed ID: 11532467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Norplant contraceptive on the bones of Nigerian women as assessed by quantitative ultrasound and serum markers of bone turnover.
    Vanderjagt DJ; Sagay AS; Imade GE; Farmer SE; Glew RH
    Contraception; 2005 Sep; 72(3):212-6. PubMed ID: 16102558
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.
    Kalogirou D; Antoniou G; Karakitsos P; Kalogirou O; Antoniou D; Giannikos L
    Int J Fertil Menopausal Stud; 1996; 41(6):522-7. PubMed ID: 9010746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immediate postabortion initiation of levonorgestrel implants reduces the incidence of births and abortions at 2 years and beyond.
    Rose SB; Garrett SM; Stanley J
    Contraception; 2015 Jul; 92(1):17-25. PubMed ID: 25818594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Keloid formation from levonorgestrel implant (Norplant System) insertion.
    Nuovo J; Sweha A
    J Am Board Fam Pract; 1994; 7(2):152-4. PubMed ID: 7857393
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A subdermal progestin implant for long-term contraception. The Medical Letter.
    Conn Med; 1991 Apr; 55(4):228. PubMed ID: 1906391
    [No Abstract]   [Full Text] [Related]  

  • 35. Delivery of progestins via the subdermal versus the intrauterine route: comparison of the pharmacology and clinical outcomes.
    Goldstuck ND; Le HP
    Expert Opin Drug Deliv; 2018 Jul; 15(7):717-727. PubMed ID: 29979891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion.
    Steinauer JE; Upadhyay UD; Sokoloff A; Harper CC; Diedrich JT; Drey EA
    Contraception; 2015 Dec; 92(6):553-9. PubMed ID: 26093190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of menorrhagia with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study.
    Wildemeersch D; Schacht E
    Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):93-101. PubMed ID: 11518454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A subdermal progestin implant for long-term contraception.
    Med Lett Drugs Ther; 1991 Mar; 33(839):17-8. PubMed ID: 1899898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Once a month administration of mifepristone improves bleeding patterns in women using subdermal contraceptive implants releasing levonorgestrel.
    Cheng L; Zhu H; Wang A; Ren F; Chen J; Glasier A
    Hum Reprod; 2000 Sep; 15(9):1969-72. PubMed ID: 10966997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characteristics of Kenyan women in a prospective cohort study who continue using subdermal contraceptive implants at 12 months.
    O'Neill E; Tang J; Garrett J; Hubacher D
    Contraception; 2014 Mar; 89(3):204-8. PubMed ID: 24360643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.